**Core tip:** Propofol is commonly used for sedation during endoscopic procedures with increasing data suggesting its superiority to other sedatives, however with reported concerns about possible adverse events. This systematic review and meta-analysis discusses different variants of propofol-based sedation and how they compare to alternative sedatives such as those utilizing benzodiazepines and opioids. We demonstrate that the use of propofol, alone or in conjunction with alternative sedatives, is safe and carries no particular negative outcomes when compared to the widely available combination of alternative sedatives using in endoscopy.

INTRODUCTION
============

In recent years, the use of propofol for sedation during endoscopy has been shown to be safe and effective. Propofol is associated with rapid onset of action and a short time to recovery of patient\'s cognitive functions post procedure\[[@B1]-[@B4]\]. Propofol may be administered alone or in combination with other sedative agents, such as benzodiazepines or opioids\[[@B5]-[@B7]\].

Sedation using propofol alone can be associated with risks and complications since it requires administration of larger doses to achieve an adequate level of sedation, which in turn can lead to dose-dependent adverse events\[[@B5],[@B8]\]. Additionally, the isolated use of this drug has disadvantages related to its pharmacokinetic properties. Propofol can induce deep sedation, has no antidote for reversibility, has a narrow therapeutic index and causes adverse events including cardiopulmonary compromise requiring resuscitation\[[@B9],[@B10]\].

However, previous studies have shown that the use of propofol as an adjunct to traditional sedatives such as benzodiazepines and opioids with moderate patient sedation is associated with lower risk of complications, improved patient cooperation and satisfaction, and shorter time to recovery post procedure\[[@B5],[@B11]\].

Several studies have compared the use of propofol alone versus its use with adjunctive sedatives\[[@B5],[@B6],[@B8],[@B12]-[@B19]\]. However, these studies included insufficient numbers of patients to produce significant and conclusive results regarding the differences between propofol and alternative sedation. In this study, we perform a systematic review and meta-analysis comparing sedation with propofol to traditional sedatives (with or without propofol) during endoscopic procedures.

MATERIALS AND METHODS
=====================

Protocol and registration
-------------------------

A protocol was established and documented prior to initiating the study to specify eligibility criteria and analytical methods for the studies included in this systematic review and meta-analysis in keeping with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This study was documented in a protocol registered in International Prospective Register of Systematic Reviews (PROSPERO) database (CRD 42017057305)\[[@B20]\].

Eligibility criteria
--------------------

Eligibility criteria were based on population, intervention, comparison, outcomes and study design strategy. Only randomized clinical trials with full texts published were included.

Search strategy, study selection and data collection process
------------------------------------------------------------

A literature search was performed using MEDLINE, Scopus, EMBASE, the Cochrane Library, Scopus, LILACS, BVS, Cochrane Central Register of Controlled Trials, and The Cumulative Index to Nursing and Allied Health Literature databases. The last search in the literature was performed on March, 2019 with no restriction regarding the idiom or the year of publication. The titles and abstracts of all potentially relevant studies were screened for eligibility. Duplicates were removed. If necessary, we accessed complementary and supplemental information in the research protocols of the studies available on the online registration platforms (for example, Clinical Trials or PROSPERO). The reference lists of studies of interest were then manually reviewed for additional articles by cross checking bibliographies. Two reviewers (Delgado AAA and Ribeiro IB) independently screened the titles and abstracts of all the articles according to predefined inclusion and exclusion criteria as described below. Any differences were resolved by mutual agreement and in consultation with the third reviewer (de Moura DTH). For the systematic review, we included studies that met all the eligibility criteria, and for the meta-analysis, those that allowed the extraction of data from text, tables or graphs. Selection process is summarized in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of included and excluded clinical trials.](WJGE-11-573-g001){#F1}

Inclusion criteria
------------------

\(1\) Adults (over 18 years of age); (2) Undergoing endoscopic examination of the gastrointestinal tract (including esophagogastroduodenoscopy. and colonoscopy); and (3) Outpatient and elective procedures.

Exclusion criteria
------------------

Studies meeting any of the following criteria were excluded: (1) Types of participants: (a) Under the age of 18 years; and (b) Group of patients with specific comorbidities (obesity, pregnant and lactating women, cardiovascular diseases, pulmonary diseases, ascites, renal failure and abdominal surgeries); (2) Types of intervention and outcomes: (a) Studies not using propofol in one of the treatment arms; (b) Studies that did not evaluate the outcomes of interest; and (c) Studies without extractable data; and (3) Intervention and control: (a) Patients receiving propofol alone or in combination with traditional combined sedative agents (benzodiazepines and opioids); and (b) Traditional combined sedatives (benzodiazepines and opioids) with or without concurrent propofol use.

Data items
----------

The following data were collected for each trial: (1) Patient characteristics; (2) Characteristics of intervention and comparison: Type of medication, doses, form of application; and (3) Outcomes as previously described.

To simplify our analysis and data representation, we chose to subdivide the included studies into different groups according to the sedation regimens administered to the intervention and control groups (Table [1](#T1){ref-type="table"}), as follows: (1) Group I - propofol *vs* benzodiazepine and opioid; (2) Group II - propofol *vs* propofol, benzodiazepine and/or opioid; and (3) Group III - propofol, benzodiazepine and opioid *vs* benzodiazepine and opioid.

###### 

Characteristics of the studies included in the meta-analysis

  **Author**         **Ref**.     **Country**   **Year**   **Patients (*n* = 3854)**   **Interven-tion**   **Interven-tion (*n* = 1834)**   **Control**                              **Control (*n* = 2004)**   **Procedure**             **Jadad**
  ------------------ ------------ ------------- ---------- --------------------------- ------------------- -------------------------------- ---------------------------------------- -------------------------- ------------------------- -----------
  Seifert            \[[@B19]\]   Germany       2000       239                         PROP                120                              PROP + MDZ                               119                        Endoscopy/ERCP            5
  Sipe               \[[@B39]\]   USA           2002       80                          PROP                40                               MDZ + MEP                                40                         Colono-scopy              4
  Vargo              \[[@B35]\]   USA           2002       75                          PROP                38                               MDZ + MEP                                37                         ERCP/EUS                  4
  Ulmer              \[[@B40]\]   USA           2003       100                         PROP                50                               MDZ + FTN                                50                         Colono-scopy              4
  Riphaus            \[[@B41]\]   Germany       2005       150                         PROP                75                               MDZ + MEP                                75                         ERCP                      5
  VanNatta           \[[@B12]\]   USA           2006       200                         PROP                50                               FTN + PROP/MDZ + PROP/MDZ + FTN + PROP   150                        Colono-scopy              3
  Fanti              \[[@B42]\]   Italy         2007       270                         PROP                135                              PROP + MDZ                               135                        EUS                       5
  Dewitt             \[[@B44]\]   USA           2008       80                          PROP                40                               MDZ + MEP                                40                         EUS                       5
  Kongkam            \[[@B43]\]   Thailand      2008       134                         PROP                67                               MDZ + MEP                                67                         ERCP                      4
  Schilling          \[[@B45]\]   Germany       2009       150                         PROP                75                               MDZ + MEP                                75                         ERCP/EUS/Enteroscopy      5
  Pascual            \[[@B26]\]   Cuba          2011       512                         PROP                256                              MDZ + MEP                                256                        Colono-scopy              4
  Lee                \[[@B25]\]   Korea         2011       222                         PROP + MDZ + MEP    102                              MDZ + MEP                                104                        Endoscopy/ERCP            5
  Chun               \[[@B31]\]   Korea         2012       135                         PROP                67                               PROP + MDZ                               68                         Stomach ESD               3
  Angsuwatcharakon   \[[@B30]\]   Thailand      2012       205                         PROP + MDZ + MEP    103                              MDZ + MEP                                102                        ERCP                      3
  Lee                \[[@B29]\]   Korea         2012       206                         PROP                104                              PROP + MDZ + FTN                         102                        ERCP/EUS                  5
  Zuo                \[[@B28]\]   China         2012       100                         PROP                49                               MDZ + FTN                                51                         Endomicroscopy            5
  Levitzky           \[[@B27]\]   USA           2012       110                         PROP + MDZ + FTN    55                               MDZ + FTN                                55                         Endoscopy                 3
  Gurbulak           \[[@B33]\]   Turkey        2014       124                         PROP                62                               MDZ + MEP                                62                         Colono-scopy              5
  Chan               \[[@B32]\]   Taiwan        2014       220                         PROP                110                              PROP + MDZ + AFTN                        110                        Endoscopy + colonoscopy   5
  Hsu                \[[@B36]\]   Taiwan        2015       100                         PROP                50                               PROP + MDZ +FTN                          50                         Endoscopy + colonoscopy   1
  Haytural           \[[@B34]\]   Turkey        2015       90                          PROP                30                               PROP + FTN/PROP + RFTN                   60                         ERCP                      1
  Li                 \[[@B38]\]   China         2016       90                          PROP                30                               PROP + FTN                               60                         Colono-scopy              3
  Schroeder          \[[@B37]\]   USA           2016       262                         PROP                126                              MDZ + FTN                                136                        Colono-scopy              4

MDZ: Midazolam; FTN: Fentanyl; PROP: Propofol; MEP: Meperidine; RFTN: Remifentanil; AFTN: Alfentanil.

Risk of bias in individual studies
----------------------------------

As treatment effect size may differ due to detection, performance, selection, and bias, the methodological evaluation of the studies was performed. The adequacy of blinding, randomization, description of withdrawals and dropouts were determined by two authors working independently, using the Jadad scale\[[@B21]\] for the evaluation of randomized clinical trials.

Statistical analysis
--------------------

This meta-analysis was performed using intention-to-treat data when possible. For all outcomes, absolute or mean risk difference was calculated. We considered statistically significant differences with 95%CI, *P* \< 0.05, using the Mantel Hantzel tests (categorical variables) or inverse variance (continuous variables).

The effects of the treatment were expressed graphically through forest plots and the heterogeneity of the studies were evaluated by the method proposed by Higgins et al\[[@B22]\], denominated *I*^2^, seeking values lower than 50%, using the fixed effect model. Risk of bias amongst studies was assessed using funnel plot analysis.

For treatment effects in which there is strong heterogeneity (*I*^2^ - 50%) test with fixed effect, we exclude studies that were outside the limits of the funnel plot and the heterogeneity was reevaluated. If there was a reduction in heterogeneity (*I*^2^ \< 50%), the excluded study was considered an outlier, that is, responsible for the high heterogeneity due to a publication bias and, consequently, it was not part of the final meta-analysis. If an outlier was not identified and the heterogeneity remained high, the Higgins et al\[[@B22]\] test was randomly selected. Review Manager 5 (RevMan 5) version 5.39 (by the Cochrane Collaboration, 2015) was the software chosen to run the meta-analysis.

Risk of bias across studies
---------------------------

Reporting bias across studies was evaluated by funnel plot graphical analysis. For each trial, the treatment effect was plotted against the measure of study precision and by Egger\'s test\[[@B23]\]. Asymmetrical funnel plot suggests the presence of reporting bias, methodological bias or true heterogeneity between smaller and larger studies.

Additional analysis
-------------------

In the presence of an asymmetrical funnel plot or high heterogeneity, (*I*^2^ ≥ 50%) a sensitivity analysis was conducted to explore how the results of the meta-analysis could change under different assumptions\[[@B24]\]. Heterogeneity and funnel plot analysis before and after the removal of each study from the meta-analysis were assessed to identify the studies accounting for inconsistency among trials. If heterogeneity was reduced to below 50% after the removal of the outlier, the corrected intervention effect estimate was applied and the results were interpreted with caution. If inconsistency did not decrease, it was considered true heterogeneity.

RESULTS
=======

Search and study selection
--------------------------

Among the 6410 articles screened from our initial search strategy, 23 randomized controlled studies were selected, including a total of 3854 patients\[[@B12],[@B19],[@B25]-[@B45]\]. Figure [1](#F1){ref-type="fig"} summarizes the selection process of the studies.

Of the 3854 patients included, 1574 received propofol as the sole sedative while 2280 received midazolam, meperidine, fentanyl, remifentanil, alfentanil in combination with propofol (Table [1](#T1){ref-type="table"}). There was wide geographical representation of studies included, encompassing a wide diversity of endoscopic procedures. The Jadad score was greater than 3 in 91.3% of the studies included in the meta-analysis, suggesting adequate methodological quality of these studies. All studies are available online, in full text format.

Results by groups
-----------------

**Group I:** In 11 studies evaluating the incidence of bradycardia, there were no observed differences between both treatment arms (RD: -0.01, 95%CI: −0.03--+0.01, *I*^2^: 22%, Figure [2A](#F2){ref-type="fig"}). In 10 studies assessing hypotension, no difference existed between both arms (RD: 0.01, 95%CI: −0.02--+0.04, *I*^2^: 0%, Figure [2B](#F2){ref-type="fig"}). The incidence of desaturation was higher in the propofol group however this did not reach statistical significance (RD: −0.03, 95%CI: −0.06--+0.00, *I*^2^: 25%, Figure [2C](#F2){ref-type="fig"}). Patient satisfaction with the visual analog scale was available in 6 of the included studies with a trend towards greater satisfaction in the benzodiazepine and/or opioid group (MD: +0.89, 95%CI: +0.62--+1.17, *I*^2^: 39%, Figure [2D](#F2){ref-type="fig"}). Endoscopist satisfaction with sedation was evaluated in only 2 studies without differences observed between both arms (MD: −0.02, 95%CI: −0.20--+0.16, *I*^2^: 0%, Figure [2E](#F2){ref-type="fig"}). Recovery time after the procedure was evaluated in 7 studies and revealed high heterogeneity. Even after withdrawal of the outlier, there was no statistical difference in recovery time between both arms (MD: -15.15, 95%CI: −31.85--+1.56, I^2^: 99%, Figure [2F](#F2){ref-type="fig"}).

![Propofol *vs* benzodiazepine associated with opioid - Forest plot of the meta-analysis. A: Comparing the occurrence of bradycardia between the propofol group and the benzodiazepine + opioid group (BZ + OP). Outcome: Bradycardia (defined as heart rate less than 50 bpm); B: Comparing the occurrence of oxygen desaturation between the propofol group and BZ + OP. Outcome: Hypotension (Defined as systolic blood pressure \< 90 mmHg); C: Comparing the occurrence of desaturation between the propofol group and BZ + OP. Outcome: Oxygen desaturation (Defined as peripheral saturation of O~2~ defined as \< 90%); D: Comparing patient satisfaction with the sedation received for the procedure between the propofol group and BZ + OP. Outcome: Patient satisfaction (Visual analog scale -- 0: very dissatisfied to 10: very satisfied); E: Comparing satisfaction of the endoscopists with the sedation administered for the procedure between the propofol group and BZ + OP. Outcome: Endoscopists satisfaction (Visual analog scale -- 0: very dissatisfied to 10: very satisfied); F: Comparing patient recovery time after the procedure between the propofol group and BZ + OP. Outcome: Post procedure time to recovery (min).](WJGE-11-573-g002){#F2}

**Group II:** Bradycardia was assessed in 5 of the included studies and had a greater trend of occurrence in the Propofol arm with benzodiazepine and/or opioid-associated compared to the propofol alone arm (RD: -0.08, 95%CI: −0.13--−0.02, *I*^2^: 59%, Figure [3A](#F3){ref-type="fig"}). In 6 studies assessing hypotension, there was no difference between the both arms (RD: -0.00, 95%CI: −0.08--+0.08, *I*^2^: 85%, Figure [3B](#F3){ref-type="fig"}). Desaturation was evaluated in 7 studies without significant difference (RD: −0.00, 95%CI: −0.03--+0.02, *I*^2^: 44%, Figure [3C](#F3){ref-type="fig"}). Patient satisfaction with the visual analog scale was available in 2 of the included studies and was different between both arms (MD: -0.62, 95%CI: -1.38--+0.13, *I*^2^: 89%, Figure [3D](#F3){ref-type="fig"}). The recovery time after the procedure was evaluated in 7 studies and the result showed high heterogeneity without statistical difference between the groups (MD: -2.04, 95%CI: −6.96--+2.88, *I*^2^: 97%, Figure [3E](#F3){ref-type="fig"}). The total dose of propofol was evaluated in 5 articles and was noted to be higher in the propofol with benzodiazepine and/or opiates arm but with high heterogeneity. The funnel-plot test did not demonstrate outliers (MD: 70.36, 95%CI: +53.11--+87.60, *I*^2^: 61%, Figure [3F](#F3){ref-type="fig"}).

![Propofol *vs* propofol with benzodiazepine and/or opioids - Forest plot of the meta-analysis. A: Comparing the occurrence of bradycardia between the propofol group and the propofol group associated with benzodiazepine and / or opioid (Prop + BZ and/or OP). Outcome: Bradycardia (defined as HR \< 50 bpm); B: Comparing the occurrence of hypotension between the propofol group and (Prop + BZ and/or OP). Outcome: Hypotension (Defined as systolic blood pressure \< 90 mmHg); C: Comparing the occurrence of desaturation between the propofol group and Prop + BZ and/or OP. Outcome: Desaturation (Defined as peripheral oxygen saturation of \< 90%); D: Comparing patient satisfaction with sedation received for the procedure between propofol group and Prop + BZ and/or OP. Outcome: Patient satisfaction (Visual analog scale - 0 very dissatisfied / 10 very satisfied); E: Comparing patient recovery time after the procedure between the propofol group and Prop + BZ and/or OP. Time to recovery (min); F: Comparing the total dose of propofol administered during procedures between the propofol group and Prop + BZ and/or OP. Outcome: Total dose of propofol given during the procedure (mg).](WJGE-11-573-g003){#F3}

**Group III:** Two studies examined the incidence of bradycardia which was not different between sedation arms (RD: -0.00, 95%CI: −0.002--+0.02, *I*^2^: 3%, Figure [4A](#F4){ref-type="fig"}). Additionally, two studies examining the incidence of hypotension showed no statistically significant differences between sedation arms (RD: 0.04, 95% CI: −0.05--+0.13, *I*^2^: 77%, Figure [4B](#F4){ref-type="fig"}). Desaturation, however, evaluated in two studies was more commonly seen with propofol + benzodiazepine + opioid arm but with high heterogeneity (RD: 0.15, 95%CI: 0.08--+0.22, *I*^2^: 95%, Figure [4C](#F4){ref-type="fig"}).

![Propofol associated with benzodiazepine and opioid *vs* benzodiazepine associated with opioid - Forest plot of the meta-analysis. A: Comparing the occurrence of bradycardia between the benzodiazepine-associated propofol group and the opioid and the benzodiazepine group associated with the opioid (BZ + OP). Outcome: Bradycardia (defined as HR \< 50 bpm); B: Comparing the occurrence of hypotension between the benzodiazepine-associated propofol group and the opioid and BZ + OP. Outcome: Hypotension (Systolic blood pressure \< 90 mmHg); C: Comparing the occurrence of desaturation between the benzodiazepine-associated propofol group and the opioid and BZ + OP. Outcome: Desaturation (Peripheral saturation of O~2~ \< 90%).](WJGE-11-573-g004){#F4}

DISCUSSION
==========

The use of propofol in endoscopy is increasingly common\[[@B46]-[@B48]\] for both diagnostic and advanced therapeutic procedures\[[@B48],[@B49],[@B58],[@B50]-[@B57]\]. Propofol has proven to be safe and affordable, yielding satisfactory and efficient sedation for patients undergoing endoscopy\[[@B59]\]. Propofol can be used as a single agent for anesthesia induction and maintenance, leads to rapid induction of anesthesia, carries a low half-life and is associated with fast recovery from anesthesia\[[@B46]\]. However, Propofol can be associated with dose-dependent complications, including the risk of major respiratory depression and several cardiovascular adverse events\[[@B54],[@B60]\].

Our study adds to the plethora of literature describing the use of propofol for endoscopy sedation, but also highlights how it compares to numerous alternative and adjunctive sedatives.

After analyzing 23 clinical trials\[[@B12],[@B19],[@B25]-[@B45]\], many of good quality and adequate methodological design, including a total of 3854 patients, we note no significant differences in many outcomes measures between the sedation arms involving propofol alone or in combination with alternative sedatives.

In contrast to the last meta-analysis published\[[@B55]\], our study demonstrates no statistical difference in outcome measures with regards to hypotension, oxygen desaturation and post-procedure anesthetic recovery when using propofol alone or in combination with benzodiazepines and/or opioids.

There was a trend towards increased incidence of bradycardia in patients in the propofol with benzodiazepine and opioid sedation arm compared to those on propofol alone. Incidence of bradycardia did not differ between other arms in the different treatment groups. No differences existed in recovery time between all sedation arms in all treatment groups as reported in the meta-analysis by Wang et al\[[@B61]\].

Previous meta-analyses\[[@B2],[@B3],[@B61]\] also demonstrated significantly fewer adverse effects with propofol sedation. In our study, we observed that propofol used alone or in conjunction with other sedatives including opioids and benzodiazepines is safe and did not result in increased adverse events in patients undergoing endoscopic procedures as demonstrated by Sethi et al\[[@B55]\] which also included sedation for advanced endoscopic procedures such as endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, and double-balloon enteroscopy.

Due to the properties of propofol, its doses are very volatile\[[@B9],[@B60]\]. Higher doses are associated with elevated cardiovascular risk and low doses are associated with several complications, especially in therapeutic procedures that cause pain. Propofol has a limited analgesic effect and higher doses are often required, when used as single agent for sedation in endoscopy. Several studies have reported that the combination of propofol with other sedative agents is a reasonable option to obtain the adequate depth of sedation, avoiding high dose-related side effects of propofol, allow for improve patient tolerance, prolong recovery time, and control of pain\[[@B5],[@B13],[@B15],[@B17]\]. However, our study did not demonstrate an advantage to propofol alone without significant statistical differences when comparing propofol to alternative agents (with and without propofol).

In our meta-analysis, patient satisfaction with the use of a visual analog scale lead to a trend towards greater satisfaction for patients undergoing sedation with benzodiazepine and opioids when compared to propofol use. The satisfaction of the endoscopists was evaluated in a few studies included in this meta-analysis however did not reveal significant differences in endoscopists satisfaction.

There are several limitations to our analysis. Similar to prior publications and meta-analysis evaluating sedation in endoscopy, we observe high heterogeneity between the several studies aggregated in the meta-analysis, which must be taken into account in the interpretation of its results.

There are several reasons for heterogeneity present in the published literature for studies included. One reason may be due to intrinsic differences in populations examined with each study, specifically age, weight, body mass which may alter the amount of sedation required and tolerability. Additionally, the education level for various populations included may influence patient satisfaction levels. Another reason for heterogeneity is lack of uniformity between the comparisons made, the individual administering sedation (anesthesiologist, non-anesthetist physicians, certified registered nurse anesthetists), acceptable and max doses of sedatives, means of sedative administration (intermittent bolus *vs* continuous infusion) and criteria for re-administration of sedative if more is required. With regards to the procedures performed, diagnostic and therapeutic interventions can have differences in total procedure times, which in turn can influence the type of sedation, doses required, level of sedation and maintenance of sedation. This can certainly influence heterogeneity.

Finally, while it is important to highlight the clinical aspects of sedation use, it is imperative to understand that cost plays a significant role in the choice of sedation. While not assessed in this study, we believe cost effectiveness should be highlighted in future sedation meta-analysis.

In conclusion, this meta-analysis suggests that the use of propofol alone or in combination with traditional adjunctive sedatives is safe and does not result in an increase in negative outcomes.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Endoscopy has transformed over the past several decades to encompass significant advances and procedural innovation, with the hope to provide better care for ill patients. However, with technical advances and innovation comes increasingly prolonged and complex procedures. This change in the endoscopic platform, alongside the higher acuity of patients, has demanded a change in the approach for procedural sedation to ensure safe interventions.

Research motivation
-------------------

The change in the sedation landscape for endoscopy over the past several decades necessitates a better understanding of sedation types and how they compare to each other for the modern practicing endocsopist.

Research objectives
-------------------

We aimed to compare sedation with propofol, alone or in combination with adjunctive sedations, to traditional sedation in endoscopy through a systematic review of the literature and meta-analysis.

Research methods
----------------

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in International Prospective Register of Systematic Reviews international database. The search was performed in the electronic databases MEDLINE (*via* PubMed), LILACS (*via* BVS) and Cochrane/Central Register of Controlled Trials. The quality of the selected papers was evaluated by Jadad score and all articles used were selected by consensus of three authors.

Research results
----------------

A total of 23 clinical trials (*n* = 3854), from an initial search of 6410 articles, were included. For Group I (Propofol *vs* benzodiazepine and/or opioids): The incidence of bradycardia, hypotension, oxygen desaturation and post procedure recovery time was not statistically different between both arms. For Group II (Propofol *vs* propofol with benzodiazepine and/or opioids): Bradycardia tended to occur in the propofol group with benzodiazepine and/or opioid-associated but there was no statistical difference in the incidence of bradycardia, desaturation or recovery time between sedation arms. For Group III (Propofol with benzodiazepine and opioid *vs* benzodiazepine and opioid): Bradycardia, desaturation and, hypotension was not statistically significant between groups.

Research conclusions
--------------------

Our findings suggest that the use of propofol alone or in combination with traditional adjunctive sedatives is safe and does not result in an increase in negative outcomes in patients undergoing endoscopic procedures.

Research perspectives
---------------------

Future studies should consider methods for standardization of sedation use to allow for less heterogeneity amongst studies and to improve analysis in future metanalyses to come. Future studies should also highlight cost effectiveness of various sedations used.
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